SARS-CoV-2 Humoral Response to mRNA Vaccine: Real-World Data From a Large Cohort of Healthcare Workers

Silva, J.; Reis, Teresa; Lopes, Cristiana; Batista-Silva, Ricardo; Ribeiro, Ricardo; Marques, Gilberto; Pacheco, Vânia; Rodrigues, Tiago; Afonso, Alexandre Ribeiro; Pinheiro, Vítor; Araújo, Lucília; Rodrigues, Fernando; Antunes, Isabel

doi:10.2139/ssrn.3933639

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, our study found that compared with male participants, female participants were at an increased risk of fever and general symptoms caused by SARS-CoV-2 and at a greater risk of symptom recovery time ≥3 days, supporting previous findings that the female sex is a risk factor for long COVID-19 (32). Vaccine responses are widely reported to be weaker in older adults, who experience immunosenescence and a more rapid waning of antibodies than younger people (33)(34)(35). We further observed that participants aged ≥60 years had a lower seropositivity rate of neutralizing antibodies against the BA.4/5 pseudovirus versus participants aged 18-59 years.…”

Section: Discussionsupporting

confidence: 86%

Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study

Xu,

Dai

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

IntroductionChina experienced a record surge of coronavirus disease 2019 cases in December 2022, during the pandemic.MethodsWe conducted a randomized, parallel-controlled prospective cohort study to evaluate efficacy and antibody duration after a fourth-dose booster with Ad5-nCoV or inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.ResultsA total of 191 participants aged ≥18 years who had completed a three-dose regimen of the inactivated SARS-CoV-2 vaccine 6 months earlier were recruited to receive the intramuscular Ad5-nCoV booster or the inactivated SARS-CoV-2 vaccine. The Ad5-nCoV group had significantly higher antibody levels compared with the inactivated vaccine group at 6 months after the fourth vaccination dose. After the pandemic, the breakthrough infection rate for the Ad5-nCoV and the inactivated vaccine groups was 77.89% and 78.13%, respectively. Survival curve analysis (p = 0.872) and multivariable logistic regression analysis (p = 0.956) showed no statistically significant differences in breakthrough infection between the two groups.DiscussionCompared with a homologous fourth dose, a heterologous fourth dose of Ad5-nCoV elicited a higher immunogenic response in healthy adults who had been immunized with three doses of inactivated vaccine. Nevertheless, the efficacy of the two vaccine types was equivalent after the pandemic.

show abstract

Section: Discussionsupporting

confidence: 86%

Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study

Xu,

Dai

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Many clinical data indicate that vaccination with a third dose of Comirnaty is useful in immunocompromised people [10,11], the chronically ill [12], or people undergoing oncological treatment [13,14]. An analysis of specific antibody concentration charts at a cut-off for SARS-CoV-2 of >0.2 AU/mL was used [10], allowing us to observe asymptomatic COVID-19 and the natural course of the disease [15].…”

Section: Discussionmentioning

confidence: 99%

“…The decline in humoral immunity over time following coronavirus infection, including SARS-CoV-2, is typical in mild cases [11,12,13,14,15,16]. Then, do all infections require antibody monitoring?…”

Section: Introductionmentioning

confidence: 99%

A New Set-up of Vanishing Antibodies: A Biennial Follow-up of Three Different Clients’ Humoral Responses Against Sars-Cov-2 After Systemic Vaccination in an Oncology Hospital in Poland

Kosiorek¹,

Stróż²,

Hryniewicz³

et al. 2022

Preprint

View full text Add to dashboard Cite

The humoral response of the COVID-19 vaccine varies from person to person. It largely depends on prior SARS-CoV-2 infection, obtaining an adequate immune response, and leaving a trace of changing antibody concentration over time. We retrospectively analyzed three clinical cases from selected patients and employees of the oncology hospital. All mild COVID-19 convalescents received the BNT162b2-Comirnaty mRNA vaccine three times. The levels of SARS-CoV-2 IgM- and IgG-specific antibodies, as well as S-RBD antibodies, were analyzed for approximately two years. The concentration of antibodies was assessed in the laboratory using the chemiluminescent immunoassay CLIA, MAGLUMI. Results: (1) Active autoimmune disease stabilized the level of IgG-specific antibodies after systemic mRNA vaccination for at least six months. (2) Post-vaccination IgG and S-RBD levels decreased when vaccination was performed within three months of onset. (3) The booster dose (third dose) administered only increased the S-RBD antibody levels. Declining IgG-specific antibodies were observed. (4) The S-RBD IgG levels were not correlated with the SARS-CoV-2 IgG levels in the vaccinated convalescents. (5) Subsequent reinfection with SARS-CoV-2 after vaccination three times released a more significant specific antibody response. Based on the collected data, we suggest that monitoring S-RBD antibodies is sensitive but not equivalent to a specific humoral response for SARS-CoV-2 IgG. We suggested that administering at least three doses of the mRNA vaccine should serve as the basis for immunization. The three-month interval may be the best alternative to an immunization schedule for non-immunocompromised people.

show abstract

SARS-CoV-2 Humoral Response to mRNA Vaccine: Real-World Data From a Large Cohort of Healthcare Workers

Cited by 2 publications

References 0 publications

Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study

Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study

A New Set-up of Vanishing Antibodies: A Biennial Follow-up of Three Different Clients’ Humoral Responses Against Sars-Cov-2 After Systemic Vaccination in an Oncology Hospital in Poland

Contact Info

Product

Resources

About